Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis

被引：0
|
作者：
Kappos, L.
Leppert, D.
Tinbergen, J.
Gerber, M.
Hauser, S. L.
机构：
[1] Univ Basel Hosp, CH-4031 Basel, Switzerland
[2] F Hoffmann La Roche Ltd, Basel, Switzerland
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
MULTIPLE SCLEROSIS JOURNAL | 2012年 / 18卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：424 / 424
页数：1
相关论文
共 50 条
  • [1] Risk of infections and malignancies after treatment with anti-CD20 monoclonal antibodies: Ocrelizumab and rituximab in rheumatoid arthritis and multiple sclerosis
    Kappos, L.
    Leppert, D.
    Tinbergen, J.
    Gerber, M.
    Hauser, S. L.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2012, 18 (12) : 1875 - 1876
  • [2] Anti-CD20 monoclonal antibodies in multiple sclerosis
    Moreno Torres, Irene
    Garcia-Merino, Antonio
    [J]. EXPERT REVIEW OF NEUROTHERAPEUTICS, 2017, 17 (04) : 359 - 371
  • [3] Anti-CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis
    Korhonen, Riku
    Moilanen, Eeva
    [J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2010, 106 (01) : 13 - 21
  • [4] Treatment of multiple sclerosis with Anti-CD20 antibodies
    Barun, Barbara
    Bar-Or, Amit
    [J]. CLINICAL IMMUNOLOGY, 2012, 142 (01) : 31 - 37
  • [5] Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab
    Alcala, C.
    Quintanilla-Bordas, C.
    Gascon-Gimenez, F.
    Sempere, A. P.
    Navarro, L.
    Carcelen-Gadea, M.
    Belenguer, A.
    Landete, L.
    Mallada, J.
    Canizares, E.
    Carratala, S.
    Cubas, L.
    Gil-Perotin, S.
    Dominguez, J. A.
    Perez-Miralles, F.
    Castillo, J.
    Casanova, B.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 672 - 673
  • [6] The mechanism of action of anti-CD20 monoclonal antibodies used in the treatment of multiple sclerosis
    Mycko, Marcin P.
    [J]. AKTUALNOSCI NEUROLOGICZNE, 2023, 23 (03): : 72 - 78
  • [7] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Finn Sellebjerg
    Morten Blinkenberg
    Per Soelberg Sorensen
    [J]. CNS Drugs, 2020, 34 : 269 - 280
  • [8] Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis
    Sellebjerg, Finn
    Blinkenberg, Morten
    Sorensen, Per Soelberg
    [J]. CNS DRUGS, 2020, 34 (03) : 269 - 280
  • [9] Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
    Delgado, Silvia R.
    Faissner, Simon
    Linker, Ralf A.
    Rammohan, Kottil
    [J]. JOURNAL OF NEUROLOGY, 2024, 271 (04) : 1515 - 1535
  • [10] Key characteristics of anti-CD20 monoclonal antibodies and clinical implications for multiple sclerosis treatment
    Silvia R. Delgado
    Simon Faissner
    Ralf A. Linker
    Kottil Rammohan
    [J]. Journal of Neurology, 2024, 271 : 1515 - 1535
12345